1-5 of 5
Mary Kelly
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nelarabine (NEL), Pegylated Asparginase (PEG) and Venetoclax (VEN) Incorporated to HCVAD Chemotherapy in the Frontline Treatment of Adult Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL)

Jayastu Senapati, Hagop M. Kantarjian, Elias Jabbour, Rodrick Babakhanlou, Tapan M. Kadia, Gautam Borthakur, Marina Y. Konopleva, William G. Wierda, Jan A. Burger, Ghayas C. Issa, Abhishek Maiti, Hayley S. Balkin, Mary Kelly, Rebecca Garris, Alessandra Ferrajoli, Guillermo Garcia-Manero, Yesid Alvarado Valero, Partow Kebriaei, Nicholas J. Short, Nitin Jain, Farhad Ravandi
Journal: Blood
Blood (2023) 142 (Supplement 1): 963.
https://doi.org/10.1182/blood-2023-179562
Published: 2023
Journal Articles

Incorporation of Nelarabine (NEL), Pegylated Asparaginase (PEG) and Venetoclax (VEN) in the Frontline Therapy of Adult Patients with T-Acute Lymphoblastic Leukemia/T-Lymphoblastic Lymphoma (T-ALL/LBL)

Rodrick Babakhanlou, Hagop Kantarjian, Elias Jabbour, Gautam Borthakur, Marina Konopleva, William G. Wierda, Jan A. Burger, Ghayas C. Issa, Abhishek Maiti, Hayley Balkin, Mary Kelly, Rebecca Garris, Alessandra Ferrajoli, Guillermo Garcia-Manero, Yesid Alvarado, Nicholas Short, Nitin Jain, Farhad Ravandi
Journal: Blood
Blood (2022) 140 (Supplement 1): 11671–11673.
https://doi.org/10.1182/blood-2022-159139
Published: 2022
Journal Articles

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

Abhishek Maiti, MBBS, Elias Jabbour, MD, Nitin Jain, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Jan A. Burger, MD PhD, William G. Wierda, MD PhD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Nicholas J. Short, MD, Stefan Faderl, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Steven M. Kornblau, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Prithviraj Bose, MD, Philip A. Thompson, MB, MS, Joseph D. Khoury, MD, Hayley Balkin, Mary Kelly, Hind Azzawi, Rebecca Garris, MSc, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–39.
https://doi.org/10.1182/blood-2020-136873
Published: 2020
Journal Articles

Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Naval G. Daver, MD, Rita Assi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Marina Y. Konopleva, MD PhD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MD MSc, Michelle Velasquez, RN, Mary Kelly, Jing Ning, PhD, Graciela M. Nogueras González, MPH, Sherry A. Pierce, BSN, BA, Dan Gombos, MD, Zeev E. Estrov, MD, Steven M. Kornblau, MD, Weiguo Zhang, MD PhD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1441.
https://doi.org/10.1182/blood-2018-99-118028
Published: 2018
Journal Articles

a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Naval Daver, MD, Rita Assi, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MDMSc, Tapan Kadia, MD, Jing Ning, PhD, Graciela Nogueras González, Sherry Pierce, BSN, BA, Mary Kelly, Weiguo Zhang, MD PhD, Dan Gombos, MD, Steven Kornblau, MD, Marina Konopleva, MD PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1344.
https://doi.org/10.1182/blood.V130.Suppl_1.1344.1344
Published: 2017